Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.08% Nasdaq Down0.83%

NPS Pharmaceuticals, Inc. (NPSP)

-NasdaqGS
25.88 Down 0.70(2.63%) 4:00PM EDT
|After Hours : 25.88 0.00 (0.00%) 4:28PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
NPS Pharmaceuticals, Inc.
550 Hills Drive
Bedminster, NJ 07921
United States - Map
Phone: 908-450-5300
Fax: 908-450-5351
Website: http://www.npsp.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:207

Business Summary 

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on NPS Pharmaceuticals, Inc.

Corporate Governance 
NPS Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 1. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Francois Nader M.D., M.B.A., 57
Chief Exec. Officer, Pres and Director
1.33M7.66M
Mr. Luke M. Beshar CPA, 55
Chief Financial Officer, Principal Accounting Officer and Exec. VP
692.00K5.24M
Ms. Susan E. Graf RPh, MBA, 41
VP of Corp. Devel. & Strategy
315.00K0.00
Dr. Roger J. Garceau M.D., FAAP, 60
Chief Medical Officer and Exec. VP
680.00K2.24M
Mr. Eric Pauwels , 52
Pres of NPS Pharma International
686.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders